A novel regulatory T cell-based therapy for patients with rheumatoid arthritis.
An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed joints of RA patients, with the aim to dampen inflammation and restore balance to the immune system.
Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.
An effector T Cell-modulating biologic for autoimmune diseases.
SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.
We are always looking for the right academic and industry partners.